Heart Failure Devices: Raising Roadblocks To Readmission
A new Medicare cost-control program aimed at reducing costly hospital readmissions has heart failure squarely in the cross-hairs, and the consequences could mean hundreds of thousands of dollars in lost Medicare revenue for hospitals that fail to meet the new readmission standards. As a result, providers are scrambling to implement programs to assess and reduce heart failure readmissions, and a growing number of device companies are touting a variety of technologies they believe could help them achieve that goal.
You may also be interested in...
Results of ADAPTIVE CRT trial show that resynchronization therapy devices with Medtronic's AdaptivCRT algorithm reduce heart failure hospitalizations.
Clinicians who work with stroke patients are beginning to look at robotics and other innovative technologies in rehabilitation that could allow for more treatments without increasing staffing. Young companies with products in development compete with established players in this market, which eventually could become more important to providers as reform efforts move ahead.
Firm preps for U.S. pivotal trial and European market launch in the third quarter for its minimally invasive, extra-aortic balloon counter-pulsation system for moderate to severe heart failure.